Etanercept
- Generic Name
- Etanercept
- Brand Names
- Enbrel, Eticovo, Benepali, Erelzi, Nepexto
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 185243-69-0
- Unique Ingredient Identifier
- OP401G7OJC
- Background
Dimeric fusion protein consisting of the extracellular ligand-binding portion of the human 75 kilodalton (p75) tumor necrosis factor receptor (TNFR) linked to the Fc portion of human IgG1. The Fc component of etanercept contains the CH2 domain, the CH3 domain and hinge region, but not the CH1 domain of IgG1. Etanercept is produced by recombinant DNA technology in a Chinese hamster ovary (CHO) mammalian cell expression system. It consists of 934 amino acids. It is used to treat or manage a variety of inflammatory conditions including rheumatoid arthritis (RA), ankylosing spondylitis (AS), and juvenile idiopathic poly-articular arthritis (JIA).
- Indication
Etanercept is indicated for the treatment of moderately to severely active rheumatoid arthritis in adults and in chronic moderate to severe plaque psoriasis in patients 4 years of age and older. It is also used to manage signs and symptoms of polyarticular idiopathic arthritis and Juvenile Psoriatic Arthritis in those aged 2 years and older. Etanercept is also used to manage the symptoms of psoriatic arthritis and ankylosing spondylitis.
- Associated Conditions
- Active Juvenile Psoriatic Arthritis, Ankylosing Spondylitis (AS), Graft-versus-host Disease (GVHD), Polyarticular Juvenile Idiopathic Arthritis, Psoriasis Vulgaris (Plaque Psoriasis), Psoriatic Arthritis, Pyoderma Gangrenosum, Rheumatoid Arthritis, Severe Plaque psoriasis, Stevens-Johnson Syndrome, Chronic, severe Psoriatic Arthritis, Moderate Plaque psoriasis, Moderate, active Rheumatoid arthritis, Severe, active Rheumatoid arthritis
- Associated Therapies
- -
Pilot Study of Etanercept (Enbrel) in Children With Fanconi Anemia
- First Posted Date
- 2009-08-25
- Last Posted Date
- 2020-09-14
- Lead Sponsor
- Children's Hospital Medical Center, Cincinnati
- Target Recruit Count
- 3
- Registration Number
- NCT00965666
- Locations
- 🇺🇸
Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
Study Evaluating Etanercept in 3 Subtypes of Childhood Arthritis
- First Posted Date
- 2009-08-20
- Last Posted Date
- 2014-06-10
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 127
- Registration Number
- NCT00962741
- Locations
- 🇪🇸
Pfizer Investigational Site, Valencia, Spain
Treatment of Hidradenitis Suppurativa Using Etanercept
- First Posted Date
- 2009-07-30
- Last Posted Date
- 2017-11-24
- Lead Sponsor
- Penn State University
- Target Recruit Count
- 20
- Registration Number
- NCT00949546
- Locations
- 🇺🇸
Penn State Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States
Study Evaluating the Efficacy and Safety of Etanercept and Acitretin in Korean Patient With Moderate to Severe Psoriasis
- Conditions
- Interventions
- First Posted Date
- 2009-07-09
- Last Posted Date
- 2012-04-09
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 60
- Registration Number
- NCT00936065
- Locations
- 🇰🇷
Pfizer Investigational Site, Seoul, Korea, Republic of
Study Evaluating Etanercept Plus Methotrexate in Early Rheumatoid Arthritis
- Conditions
- Interventions
- First Posted Date
- 2009-06-04
- Last Posted Date
- 2014-07-17
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 306
- Registration Number
- NCT00913458
- Locations
- 🇬🇧
Pfizer Investigational Site, Newcastle Upon Tyne, United Kingdom
Effects of Etanercept on the Heart, Veins and Thickness of Certain Major Arteries In Ankylosing Spondylitis Patients
- First Posted Date
- 2009-05-29
- Last Posted Date
- 2016-01-13
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 34
- Registration Number
- NCT00910273
- Locations
- 🇮🇹
Pfizer Investigational Site, Roma, Italy
Study of Islet Transplantation in Type 1 Diabetic Kidney Transplant Recipients
- Conditions
- Interventions
- First Posted Date
- 2009-04-27
- Last Posted Date
- 2017-11-29
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 7
- Registration Number
- NCT00888628
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
Study Evaluating Etanercept in Subjects With Ankylosing Spondylitis in Spain
- Conditions
- Interventions
- First Posted Date
- 2009-04-02
- Last Posted Date
- 2010-04-28
- Lead Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
- Target Recruit Count
- 108
- Registration Number
- NCT00873730
Study Comparing The Effect On Disease Activity When Reducing Or Discontinuing Etanercept In Subjects With RA
- First Posted Date
- 2009-03-10
- Last Posted Date
- 2013-09-11
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 91
- Registration Number
- NCT00858780
- Locations
- 🇸🇪
Pfizer Investigational Site, Uppsala, Sweden
A Randomized, Double Blind, Placebo Controlled Study of Etanercept in Children With Kawasaki Disease
- Conditions
- Interventions
- First Posted Date
- 2009-02-11
- Last Posted Date
- 2023-05-06
- Lead Sponsor
- Michael Portman
- Target Recruit Count
- 205
- Registration Number
- NCT00841789
- Locations
- 🇺🇸
Texas Children's Hospital, Houston, Texas, United States
🇺🇸Seattle Children's Hospital, Seattle, Washington, United States
🇺🇸Primary Children's Medical Center, Salt Lake City, Utah, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.